“We are pleased with our strong year-over-year revenue growth and continued momentum in international markets,” said David Pidduck, CEO of MediPharm Labs (MEDIF). “While the second quarter included the cost and distraction of a proxy contest, our team remained focused and delivered solid results. I want to thank our shareholders again for their continued support and engagement. We are aligned in our vision to build a profitable, cash flow-positive business, and remain confident in our path forward.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDIF:
- MediPharm Labs Poised for Growth Amid Potential U.S. Cannabis Rescheduling
- MediPharm Labs to Announce Q2 2025 Financial Results
- MediPharm Labs Expands CBN Portfolio with New Nighttime Inhaler
- Medipharm Labs announces launch of new Shake & Puff CBN THC inhaler
- MediPharm Labs Announces 2025 Shareholder Meeting Results and Board Changes